Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

228

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions

Triple Negative Breast Cancer

Interventions

DRUG

Gemcitabine and carboplatin plus antibiotic (moxifloxacin)

Standard chemotherapy (gemcitabine and carboplatin) plus antibiotic (moxifloxacin)

DRUG

Gemcitabine combined with carboplatin plus placebo

Standard chemotherapy (gemcitabine and carboplatin) plus placebo

Trial Locations (1)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER